116 related articles for article (PubMed ID: 29750310)
1. Mina53 nuclear localization is an important indicator of prognosis in patients with colorectal cancer after adjuvant chemotherapy.
Fujino S; Kinugasa T; Sudo T; Mizobe T; Yoshida T; Yoshida N; Ohchi T; Tajiri K; Yuge K; Nagasu S; Katagiri M; Akagi Y
Oncol Rep; 2018 Jul; 40(1):101-110. PubMed ID: 29750310
[TBL] [Abstract][Full Text] [Related]
2. PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma.
Buhmeida A; Bendardaf R; Hilska M; Laine J; Collan Y; Laato M; Syrjänen K; Pyrhönen S
Ann Oncol; 2009 Jul; 20(7):1230-5. PubMed ID: 19276398
[TBL] [Abstract][Full Text] [Related]
3. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the myc target gene Mina53 in advanced renal cell carcinoma.
Ishizaki H; Yano H; Tsuneoka M; Ogasawara S; Akiba J; Nishida N; Kojiro S; Fukahori S; Moriya F; Matsuoka K; Kojiro M
Pathol Int; 2007 Oct; 57(10):672-80. PubMed ID: 17803656
[TBL] [Abstract][Full Text] [Related]
5. [Predictive value of combination detection of tissue Pgp1 expression and preoperative serum CEA level for colorectal cancer].
Wu F; Chen L; Wu W; Jiang B; Su X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):443-449. PubMed ID: 28440527
[TBL] [Abstract][Full Text] [Related]
6. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
[TBL] [Abstract][Full Text] [Related]
7. Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study.
Sgouros J; Aravantinos G; Kouvatseas G; Rapti A; Stamoulis G; Bisvikis A; Res H; Samantas E
J Gastrointest Cancer; 2015 Dec; 46(4):343-9. PubMed ID: 26143067
[TBL] [Abstract][Full Text] [Related]
8. Lymph Node Ratio as a Risk Factor for Recurrence After Adjuvant Chemotherapy in Stage III Colorectal Cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Nishimura Y; Katoh H; Yamashita K; Watanabe M; Yamaguchi K
J Gastrointest Surg; 2017 May; 21(5):867-878. PubMed ID: 28251467
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Watanabe T
J Surg Res; 2016 Oct; 205(2):384-392. PubMed ID: 27664887
[TBL] [Abstract][Full Text] [Related]
10. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
[TBL] [Abstract][Full Text] [Related]
11. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
13. KRT17 as a prognostic biomarker for stage II colorectal cancer.
Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
[TBL] [Abstract][Full Text] [Related]
14. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
15. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
Yang XQ; Chen C; Wang FB; Peng CW; Li Y
Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
[TBL] [Abstract][Full Text] [Related]
17. Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer.
Park HS; Jung M; Shin SJ; Heo SJ; Kim CG; Lee MG; Beom SH; Lee CY; Lee JG; Kim DJ; Ahn JB
Ann Surg Oncol; 2016 Mar; 23(3):928-35. PubMed ID: 26514121
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological Factors Associated with Recurrence and Prognosis after R0 Resection for Stage IV Colorectal Cancer with Peritoneal Metastasis.
Sato H; Kotake K; Sugihara K; Takahashi H; Maeda K; Uyama I;
Dig Surg; 2016; 33(5):382-91. PubMed ID: 27119565
[TBL] [Abstract][Full Text] [Related]
20. A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer.
Sho S; Court CM; Winograd P; Russell MM; Tomlinson JS
J Surg Oncol; 2017 Dec; 116(8):996-1004. PubMed ID: 28767131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]